| Date | Form | Description | Docs | XBRL | Pages |
| 01/04/22 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
63 |
| 12/09/21 | 8-K | Current report filing |
|
|
2 |
| 11/02/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 11/01/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 11/01/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/28/21 | 8-K | Current report filing |
|
|
2 |
| 10/04/21 | 8-K | Current report filing |
|
|
2 |
| 09/03/21 | SC 13D/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities |
|
2 | |
| 09/01/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
20 |
| 07/28/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...